A review of the effects of vitamins and other dietary supplements on seizure activity

Epilepsy and Behavior

Volumn 18, Issue 3, 2010, Pages 139-150

  Lee, Susan W ^a   Chung, Steve S ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Caffeine; Dietary supplements; Epilepsy; Folic acid; Melatonin; Omega 3 fatty acid; Seizures; Selenium; Theophylline; Vitamin E;

Indexed keywords

ALPHA TOCOPHEROL; AMINOPHYLLINE; BENZOIC ACID; CAFFEINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOBAZAM; CYANOCOBALAMIN; DIAZEPAM; DOCOSAHEXAENOIC ACID; ETHYLENEDIAMINE; FOLIC ACID; FOLINIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; MAGNESIUM SULFATE; MANGANESE; MELATONIN; NIMODIPINE; OMEGA 3 FATTY ACID; PETHIDINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROMETHAZINE; RETINOL; SELENIUM; THEOPHYLLINE; VALPROIC ACID; VITAMIN D; VITAMIN;

ANTICONVULSANT ACTIVITY; ANTIOXIDANT ACTIVITY; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONVULSION; DERMATITIS; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EPILEPSY; EPILEPTIC STATE; FREEZING; GAIT DISORDER; HAIR LOSS; HUMAN; HYPERVENTILATION; INTRACTABLE EPILEPSY; LETHARGY; MATERNAL MORTALITY; MONOTHERAPY; NAUSEA; NONHUMAN; PARKINSONISM; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; TEMPORAL LOBE EPILEPSY; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; VITAMIN SUPPLEMENTATION; VOMITING; DIET THERAPY;

DIETARY SUPPLEMENTS; HUMANS; SEIZURES; VITAMINS;

EID: 77954387333     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.04.013     Document Type: Review

References (111)

1. Shorvon S. Handbook of epilepsy treatment 2005, Blackwell, Nantucket, MA. 2nd ed.
2. Kwan P., Brodie M. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
3. World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs999/en/index.html. Accessed: April 2009.
4. Marrow J.D., Edeki T.I., Mouelhi M.E., et al. ASCPT position statement: American Society For Clinical Pharmacology and Therapeutics position statement on dietary supplement safety and regulation. Clin Pharmacol Ther 2005, 77:113-122.
5. Guyton A.C., Hall J.E. Textbook of medical physiology 1996, Saunders, Philadelphia. 9th ed.
6. Fishman R.A. Neurological aspects of magnesium metabolism. Arch Neurol 1965, 12:562-569.
7. Nuytten D., Van Hees J., Meulemans A., Carton H. Magneisum deficiency as a casue of acute intractable seizures. J Neurol 1991, 238:262-264.
8. Weisleder P., Tobin J.A., Kerrigan J.F., Bodensteiner J.B. Hypomagnesemic seizures: case report and presumed pathophysiology. J Child Neurol 2002, 17:59-61.
9. Visudhiphan P., Visudtibhan A., Chiemchanya S., Khongkhatithum C. Neonatal seizures and familial hypomagnesemia with secondary hypocalcemia. Pediatr Neurol 2005, 33:202-205.
10. Mody I., Lambert J.D., Heinemann U. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J Neurophysiol 1987, 57:869-888.
11. Sood A.K., Handa R., Malhotra R.C., Gupta B.S. Serum CSF, RBC and urinary levels of magnesium and calcium in idiopathic generalised tonic clonic seizures. Indian J Med Res 1993, 98:152-154.
12. Sinert R., Zehtabchi S., Desai S., et al. Serum ionized magnesium and calcium levels in adult patients with seizures. Scand J Clin Lab Invest 2007, 67:317-326.
13. Benga I., Baltescu V., Tilinca R., et al. Plasma and cerebrospinal fluid concentrations of magnesium in epileptic children. J Neurol Sci 1985, 67:29-34.
14. Oladipo O.O., Ajala M.O., Okubadejo N., Danesi M.A., Afonja O.A. Plasma magnesium in adult Nigerian patients with epilepsy. Nigerian Postgrad Med J 2003, 10:234-237.
15. Will A.D., Lewis K.L., Hinshaw D.B., et al. Cerebral vasoconstriction in toxemia. Neurology 1987, 37:1555-1557.
16. Sadeh M. Action of magnesium sulfate in the treatment of preeclampsia-eclampsia. Stroke 1989, 20:1273-1275.
17. Altman D., Carroli G., Duley L., et al. for the Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002, 359:1877-1890.
18. The Eclampsia Trial Collaborative Group Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995, 345:1455-1463.
19. Duley L., Henderson-Smart D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst. Rev. 2003, 4:CD000128.
20. Duley L., Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst. Rev. 2000, 2:CD000127.
21. Duley L., Gulmezoglu A.M. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev 2001, 1:CD002960.
22. Belfort M.A., Anthony J., Saade G.R., Allen J.C. for the Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med 2003, 348:304-311.
23. Coetzee E.J., Dommisse J., Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998, 105:300-303.
24. Duley L., Gülmezoglu A.M., Henderson-Smart D.J. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2003, 2:CD000025.
25. Tanyel M.C., Mancano L.D. Neurologic findings in vitamin E deficiency. Am Fam Physician 1997, 55:197-201.
26. Sullivan C., Capaldi N., Mack G., Buchanan N. Seizures and natural vitamin E [letter]. Med J Aust 1990, 152:613-614.
27. Ogunmekan A.O., Hwang P.A. A randomized, double-blind, placebo-controlled, clinical trial of D-alpha-tocopheryl acetate (vitamin E), as add-on therapy, for epilepsy in children. Epilepsia 1989, 30:84-89.
28. Hom A.C., Weaver R.C., Alderson J.J. Efficacy of D-alpha tocopheryl acetate as adjunctive antiepileptic agent in patients with refractory epilepsy and profound developmental disability: a prospective, randomized, double-blind, placebo-controlled trial. Epilepsia 1991, 32(Suppl. 3):62.
29. Raju G.B., Behari M., Prasad K., Ahuja G.K. Randomized, double blind, placebo-controlled, clinical trial of D-alpha-tocopherol (vitamin E) as add-on therapy in uncontrolled epilepsy. Epilepsia 1994, 352:368-372.
30. Miller E.R., Pastor-Barriuso R., Dalal D., et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 1421:37-46.
31. Xiao Y., Li X. Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res 1999, 846:112-121.
32. Yehuda S., Carasso R.L., Mostofsky D.I. Essential fatty acid preparation (SR-3) raises the seizure threshold in rats. Eur J Pharmacol 1994, 254:193-198.
33. Yuen A.W.C., Sander J.W., Fluegel D., et al. Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial. Epilepsy Behav 2005, 7:253-258.
34. Schlanger S., Shinitzky M., Yam D. Diet enriched with omega-3 fatty acids alleviates convulsion symptoms in epilepsy patients. Epilepsia 2002, 43:103-104.
35. Bromfield E., Dworetzky B., Hurwitz S., et al. A randomized trial of polyunsaturated fatty acids for refractory epilepsy. Epilepsy Behav 2008, 12:187-190.
36. Yuen A.W.C., Sander J.W. Is omega-3 fatty acid deficiency a factor contributing to refractory seizures and SUDEP? A hypothesis. Seizure 2004, 13:104-107.
37. DeGiorgio C.M., Miller P., Meymandi S., Gornbein J.A. N-3 fatty acids (fish oil) for epilepsy, cardiac risk factors, and risk of SUDEP: clues from a pilot, double-blind, exploratory study. Epilepsy Behav 2008, 13:681-684.
38. Scorza F.A., Cysneiros R.M., Arida R.M., et al. The other side of the coin: beneficiary effect of omega-3 fatty acids in sudden unexpected death in epilepsy. Epilepsy Behav 2008, 13:279-283.
39. Taha A.Y., Ciobanu F.A., Saxena A., Burnham W.M. Assessing the link between omega-3 fatty acids, cardiac arrest, and sudden unexpected death in epilepsy. Epilepsy Behav 2009, 14:27-31.
40. O'Keffe J.H., Abuissa H., Sastre A., Steinhaus D.M., Harris W.S. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 2006, 97:1127-1130.
41. Christensen J.H., Gustenhoff P., Korup E., et al. Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomized controlled trial. Br Med J 1996, 312:677-678.
42. Marchioli R., Barzi F., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105:1897-1903.
43. Available at: http://clinicaltrials.gov/ct2/show/NCT00871377?term=omega+3+and+SUDEP&rank=1. Accessed: March 2010.
44. Moore J.L. The significance of folic acid for epilepsy patients. Epilepsy Behav 2005, 7:172-181.
45. Reynolds E.H. Benefits and risk of folic acid to the nervous system. J Neurol Neurosurg Psychiatry 2002, 72:567-571.
46. Coull B.M., Malinow M.R., Beamer N., et al. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990, 21:572-576.
47. MRC Vitamin Study Research Group Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991, 338:131-137.
48. Spina bifida and anencephaly before and after folic acid mandate-United States, 1995-1996 and 1999-2000. Morbid Mortal Wkly Rep 2004, 53:362-365. Centers for Disease Control and Prevention (CDC).
49. Rosa F.W. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991, 324:674-677.
50. Omtzigt J.G., Los F.J., Grobbee D.E., et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992, 42(4, Suppl. 5):119-125.
51. Morrow J., Russell A., Guthrie E., et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006, 77:193-198.
52. Harden C.L., Pennell P.B., Koppel B.S., et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009, 73:142-149.
53. Jensen O.N., Olesen O.V. Subnormal serum folate due to anticonvulsive therapy. Arch Neurol 1970, 22:181-182.
54. Grant R.H.E., Stores O.P.R. Folic acid in folate-deficient patients with epilepsy. Br Med J 1970, 4:644-648.
55. Mattson R.H., Gallagher B.B., Reynolds E.H., Glass D. Folate therapy in epilepsy: a controlled study. Arch Neurol 1973, 29:78-81.
56. Gibberd F.B., Nicholls A., Wright M.G. The influence of folic acid on the frequency of epileptic attacks. Eur J Clin Pharmacol 1981, 19:57-60.
57. Obbens E.A., Hommes O.R. The epileptogenic effects of folate derivatives in the rat. J Neurol Sci 1973, 20:223-229.
58. Reynolds E.H. Effects of folic acid on the mental state and fit-frequency of drug-treated epileptic patients. Lancet 1967, 1:1086-1088.
59. Guidolin L., Vignoli A., Canger R. Worsening in seizure frequency and severity in relation to folic acid administration. Eur J Neurol 1998, 5:301-303.
60. Muñoz-Hoyos A., Sánchez-Forte M., Molina-Carballo A., et al. Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. J Child Neurol 1998, 13:501-509.
61. Brzezinski A. Melatonin in humans. N Engl J Med 1997, 336:186-195.
62. Mevissen M., Ebert U. Anticonvulsant effects of melatonin in amygdala-kindled rats. Neurosci Lett 1998, 257:13-16.
63. Champney T.H., Hanneman W.H., Legare M.E., Appel K. Acute and chronic effects of melatonin as an anticonvulsant in male gerbils. J Pineal Res 1996, 20:79-83.
64. Bazil C.W., Short D., Crispin D., Zheng W. Patients with intractable epilepsy have low melatonin, which increases following seizures. Neurology 2000, 55:1746-1748.
65. Gupta M., Gupta Y.K., Agarwal S., Aneja S., Kohli K. A randomized, double-blind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes. Br J Clin Pharmacol 2004, 58:542-547.
66. Fauteck J., Schmidt H., Lerchl A., Kurlemann G., Wittkowski W. Melatonin in epilepsy: first results of replacement therapy and first clinical results. Biol Signals Recept 1999, 8:105-110.
67. Peled N., Shorer Z., Peled E., Pillar G. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia 2001, 42:1208-1210.
68. Jones C., Huyton M., Hindley D. Melatonin and epilepsy. Arch Dis Child 2005, 90:1203.
69. Madhur G., Aneja S., Kohli K. Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized, double-blind, placebo-controlled trial. Epilepsy Behav 2004, 5:316-321.
70. Sheldon S. Proconvulsant effects of oral melatonin in neurologically disabled children. Lancet 1998, 351:1254.
71. Toxicological profile for manganese (Draft for Public Comment) 2008, Agency for Toxic Substances and Disease Registry (ATSDR, U.S. Department of Health and Human Services, Public Health Service, Atlanta, GA.
72. Dickerson R.N. Manganese intoxication and parenteral nutrition. Nutrition 2001, 17:689-693.
73. Huang C.C., Lu C.S., Chu N.S., et al. Progression after chronic manganese exposure. Neurology 1993, 43:1479-1483.
74. Fitzgerald K., Mikalunas V., Rubin H., et al. Hypermanganesemia in patients receiving total parenteral nutrition. J Parenteral Enteral Nutr 1999, 23:333-336.
75. Hsieh C., Liang S., Peng S.S., Lee W. Seizure associated with total parenteral nutrition-related hypermanganesemia. Pediatr Neurol 2007, 36:181-183.
76. Gonzalez-Reyes R.E., Gutierez-Alvarez A.M., Moreno C.B. Manganese and epilepsy: a systematic review of the literature. Brain Res Rev 2007, 53:332-336.
77. Dietary reference intakes: elements. U.S. Department of Agriculture. Available at: http://www.iom.edu/Global/NewsAnnouncements//media/48FAAA2FAAA2FD9E74D95BBDA2236E7387B49.ashx. Accessed: January 2010.
78. Hurley L.S., Woolley D.E., Rosenthal F., Timiras P.S. Influence of manganese on susceptibility of rats to convulsions. Am J Physiol 1963, 204:493-496.
79. Papavasiliou P.S., Kutt H., Miller S.T., et al. Seizure disorders and trace metals: manganese tissue levels in treated epileptics. Neurology 1979, 29:1466-1473.
80. Dupont C.L., Tanaka Y. Blood manganese levels in children with convulsive disorder. Biochem Med 1985, 33:246-255.
81. Carl G.F., Keen C.L., Gallagher B.B., et al. Association of low blood manganese concentrations with epilepsy. Neurology 1986, 36:1584-1587.
82. Akram M., Sullivan C., Mack G., Buchanan N. What is the clinical significance of reduced manganese and zinc levels in treated epileptic patients?. Med J Aust 1989, 151:113.
83. Davidson D.L.W., Ward N.I. Abnormal aluminium, cobalt, manganese, strontium and zinc concentrations in untreated epilepsy. Epilepsy Res 1988, 2:323-330.
84. Papavasiliou P.S., Miller S.T. Generalized seizures alter the cerebral and peripheral metabolism of essential metals in mice. Exp Neurol 1983, 82:223-236.
85. Carl G.F., Critchfield J.W., Thompson J.L., et al. Genetically epilepsy-prone rats are characterized by altered tissue trace element concentrations. Epilepsia 1990, 31:247-252.
86. Komaki H., Maisawa S., Sugai K., Kobayashi Y., Hashimoto T. Tremor and seizures associated with chronic manganese intoxication. Brain Dev 1999, 21:122-124.
87. Rotruck J.T., Pope A.L., Ganther H.E., et al. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973, 179:588-590.
88. Rayman M.P. The importance of selenium to human health. Lancet 2000, 356:233-241.
89. Saliba W., El Fakih R., Shaheen W. Heart failure secondary to selenium deficiency, reversible after supplementation. Int J Cardiol 2008, Available online 6 December 2008.
90. Zou K., Liu G., Wu T., Du L. Selenium for preventing Kashin-Beck osteoarthropathy in children: a meta-analysis. Osteoarthritis Cartilage 2009, 17:144-151.
91. Spiller H.A., Pfiefer E. Two fatal cases of selenium toxicity. Forens Sci Int 2007, 171:67-72.
92. Sutter M.E., Thomas J.D., Brown J., Morgan B. Selenium toxicity: a case of selenosis caused by a nutritional supplement. Ann Intern Med 2008, 48:970-971.
93. Spallholz J.E., Boylan L.M., Larsen H.S. Advances in understanding selenium's role in the immune system. Ann NY Acad Sci 1990, 587:123-139.
94. Turkdogan D., Toplan S., Karakoc Y. Lipid peroxidation and antioxidative enzyme activities in childhood epilepsy. J Child Neurol 2002, 17:673-676.
95. Patel M. Mitochondrial dysfunction and oxidative stress: cause and consequence of epileptic seizures. Free Radic Biol Med 2004, 1951-1962.
96. Willmore L.J., Rubin J.J. Antiperoxidant pretreatment and iron-induced epileptiform discharges in the rat: EEG and histopathologic studies. Neurology 1981, 31:63-69.
97. Ramaekers V.T., Calomme M., Berghe V., Makropoulos W. Selenium deficiency triggering intractable seizures. Neuropediatrics 1994, 25:217-223.
98. Ashrafi M.R., Shabanian R., Abbaskhanian A., et al. Selenium and intractable epilepsy: is there any correlation?. Pediatr Neurol 2007, 37:25-29.
99. Weber G., Maertens P., Meng X., Pippenger C.E. Glutathione peroxidase deficiency and childhood seizures. Lancet 1991, 337:1443-1444.
100. Ashrafi M.R., Shams S., Nouri M., et al. A probable causative factor for an old problem: selenium and glutathione peroxidase appear to play important roles in epilepsy pathogenesis. Epilepsia 2007, 48:1750-1755.
101. Nehlig A., Daval J., Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic, and psychostimulant effects. Brain Res Rev 1992, 17:139-170.
102. Gilbert R.M., Marshman J.A., Schwieder M., Berg R. Caffeine content of beverages consumed. Can Med Assoc J 1976, 114:205-208.
103. Chu N. Caffeine and aminophylline induced seizures. Epilepsia 1981, 22:85-94.
104. Pentel P. Toxicity of over-the-counter stimulants. JAMA 1984, 252:1898-1903.
105. Francis A., Fochtmann L. Caffeine augmentation of electroconvulsive seizures. Psychopharmacology 1994, 115:320-324.
106. Coffey C.E., Figiel G.S., Weiner R.D., Saunders W.B. Caffeine augmentation of ECT. Am J Psychiatry 1990, 147:579-585.
107. Gasior M., Borowicz K., Kleinrok Z., Czuczwar S. Chronic caffeine and the anti-convulsant potency of antiepileptic drugs against maximal electroshock. Pharmacol Biochem Behav 1996, 54:639-644.
108. Kaufman K., Sachdeo R.C. Caffeinated beverages and decreased seizure control. Seizure 2003, 12:519-521.
109. Shum S., Seale C., Hathaway D., Chucovich V., Beard D. Acute caffeine ingestion fatalities: management issues. Vet Hum Toxicol 1997, 39:228-230.
110. Zwillich C.W., Sutton F.D., Neff T.A., et al. Theophylline-induced seizures in adults: correlation with serum concentrations. Ann Intern Med 1975, 82:784-787.
111. Oki J., Yamamoto M., Yanagawa J., et al. Theophylline-induced seizures in a 6-month-old girl serum and cerebrospinal fluid levels. Brain Dev 1994, 16:162-164.